Clinical trials: HCV Infection
Chronic Hepatitis C
Evaluation of the National Treatment Program of Hepatitis C in Egypt
The aim of the study is to analyse data coming from two treatment centres of the National Treatment Program Centres of hepatitis C in Egypt
- Trial name
- eNTC (NCT02101177)
- Where
- 2 sites in Egypt
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis B, Human Immunodeficiency Virus
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients
Confirm the safety of maraviroc when used as a component of combination antiretroviral therapy in HIV and Hepatitis co-infected patients.
- Conditions
- Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic
- Trial name
- NCT00782301
- Testing
- maraviroc, etravirine
- Where
- 18 sites in United States, Canada and 1 more
- Sponsor
- ViiV Healthcare
Hepatitis C, Chronic, Liver Diseases
Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) Patients
In order to persist in the liver, HCV has numerous nonspecific and specific strategies to overcome the immunity of the host. The crucial step in the establishment of viral persistence and chronic hepatitis is the avoidance of…
- Conditions
- Hepatitis C, Chronic, Liver Diseases, Virus Diseases
- Trial name
- NCT01062659
- Where
- Germany
- Sponsor
- University of Ulm
Depression, HIV Infections
Trial of Citalopram for the Prevention of Depression
With the improved prognosis of human immunodeficiency virus (HIV) infection, end stage liver disease due to hepatitis C (HCV) now represents a major cause of morbidity and mortality in people with HIV.
- Conditions
- Depression, HIV Infections, Hepatitis C
- Trial name
- PICCO (NCT00317746)
- Testing
- Citalopram
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- Marina Klein
Hepatitis C
The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital
The Prime Study is a randomised trial investigating models of care for hepatitis C in the era of direct acting antiviral (DAA) therapy.
- Trial name
- NCT02555475
- Testing
- community based hepatitis C care and treatment
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 140 people
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Chronic Hepatitis C Genotype 1B, Metabolic Syndrome
Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b
This is a multi-center, open-label trial of Elbasvir/ Grazoprevir 50/100 mg fixed dose combination 12 week treatment aimed to evaluate SVR12 in treatment naïve patients with chronic hepatitis C (genotype 1b) infection, associated…
- Conditions
- Chronic Hepatitis C Genotype 1B, Metabolic Syndrome, Fibrosis, Liver, Cirrhoses, Liver
- Trial name
- NCT03222167
- Testing
- Elbasvir/ Grazoprevir 50/100 mg fixed dose combination
- Where
- Kazakhstan
- Volunteers
- 60 people
- Sponsor
- Institute Of Cardiology & Internal Diseases, Kazakhstan
Hepatitis C
In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia
The standard treatment of chronic hepatitis C infection is pegylated interferon alpha combined with ribavirin. Anaemia is a common complication occurring in up to 30% of subjects.
- Trial name
- NCT01726400
- Testing
- Pegylated interferon alpha, Ribavirin
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Fremantle Hospital and Health Service
Hepatitis C, Genotype 3
Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders
When administered simultaneously, interferon-alpha 2b + interferon-gamma result in dramatic antiviral synergy.Ribavirin has shown to enhance interferon-gamma levels in patients with chronic hepatitis C treated with…
- Conditions
- Hepatitis C, Genotype 3, Non-responders, Relapsers
- Trial name
- NCT00538811
- Testing
- interferon alpha-2b, ribavirin, interferon-gamma,, interferon alpha-2b, ribavirin, amantadine
- Where
- 2 sites in Pakistan
- Volunteers
- 40 people
- Sponsor
- Aga Khan University
Hepatitis C, Chronic
Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO
This is a Phase IV, open-label, multi-center study to evaluate the real world sustained virological response rate, subject adherence, and subject reported outcomes during and after treatment of non-cirrhotic genotype 1 chronic…
- Trial name
- NCT02461745
- Testing
- ombitasvir, paritaprevir/r, dasabuvir + ribavirin, ombitasvir, paritaprevir/r, dasabuvir
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Kaiser Permanente
Hepatitis C, Chronic
Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients
The aim of this trial is to evaluate efficacy and safety of treatment with 600 mg of BID BI 207127 in combination with 120 mg QD Faldaprevir and RBV compared to a Telaprevir-based regimen along with PegIFN and RBV in chronically…
- Trial name
- NCT01858961
- Testing
- BI 201335, ribavirin, BI 207127
- Where
- 12 sites in Australia, Spain and 1 more
- Sponsor
- Boehringer Ingelheim
Healthy Volunteer
TMC649128HPC1001 - First In-human Trial to Examine Safety, Tolerability, and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses of TMC649128 in Healthy Volunteers
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability of single oral doses of TMC649128 in healthy volunteers.
- Trial name
- NCT01288677
- Testing
- TMC649128
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Chronic Hepatitis C Infection
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
The purpose of this study is to study the effects of valacyclovir on patients who have hepatitis C and antibodies to herpes simplex type-2. Herpes simplex type 2 is a virus which causes genital herpes.
- Trial name
- NCT01453075
- Testing
- Valacyclovir
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Drug Use, HCV Infection
A Community-based Intervention Among Active Drug Users in Montpellier
The study aims to assess the effectiveness of a community-based model of HCV mass screening associated with an immediate HCV treatment on the cascade of care among active drug users (DUs) in the city of Montpellier, France.
- Trial name
- ICONE (NCT04008927)
- Testing
- HCV screening, Diagnosis of hepatitis C, HCV treatment
- Where
- France
- Volunteers
- 554 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Obesity, Insulin Resistance
Lifestyle Intervention Targetting Obesity and Insulin Resistance in Chronic Hepatitis C
Chronic hepatitis C (CHC) infection affects approximately 1 in 100 Canadians. Untreated, CHC has significant long-term consequences including cirrhosis, liver cancer and liver failure.
- Conditions
- Obesity, Insulin Resistance, Metabolic Syndrome, Hepatitis C
- Trial name
- NCT00755742
- Testing
- Lifestyle intervention
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- University Health Network, Toronto
Chronic Hepatitis C, Menopause
Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)
The cohort of post-menopausal women represents a group of very-difficult-to-treat patients in whom a more powerful approach is required in order to improve the disappointing response rate.
- Trial name
- MEN_BOC (NCT01457937)
- Testing
- Pegylated Interferon, Ribavirin, Boceprevir
- Where
- Italy
- Volunteers
- 240 people
- Sponsor
- University of Modena and Reggio Emilia
Hepatitis C, Infectious Disease
HepCare: The Effectiveness of Community Based Interventions With Peer Support to Improve Case Detection, Carry Out Pre-treatment Assessments and Assist Underserved Populations Through HCV Treatment
Hepatitis C infection is a major cause of chronic liver disease and death with approximately 3% of the world's population is infected with hepatitis C virus (HCV).
- Trial name
- NCT03524794
- Where
- United Kingdom
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- University College, London
Hepatitis C, Chronic
Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C
We perform this study to identity efficacy and safety of Daclatasvir and Asunaprevir in real practice.
- Trial name
- ESDAC (NCT02639585)
- Testing
- Daclinza and Sunvepra
- Where
- 2 sites in South Korea
- Volunteers
- 32 people
- Sponsor
- Pusan National University Hospital
Hepatitis C
A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response
This study is being conducted to learn more about the safety and effect of telaprevir in combination with peginterferon alfa-2a (PEG-IFN) and ribavirin (RBV) in participants with hepatitis C who have never been treated for their…
- Trial name
- NCT00758043
- Testing
- telaprevir, ribavirin, peginterferon alfa-2a
- Where
- 82 sites in United States, Belgium and 2 more
- Volunteers
- 540 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic
Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)
This is a multicenter clinical trial designed to compare the efficacy of 48 weeks of therapy with pegylated (PEG)-Interferon/ribavirin in Southeastern Asian patients with genotype 1 chronic hepatitis C with 48 weeks of therapy…
- Trial name
- NCT00255008
- Testing
- peginterferon alfa-2b, ribavirin
- Volunteers
- 121 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus (HCV)
A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs
Post-marketing surveillance study to evaluate the real world safety and effectiveness of Viekira/ Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) administered under a normal, routine treatment practice by Korean…
- Trial name
- HCV PMS (NCT03201718)
- Where
- 59 sites in South Korea
- Volunteers
- 505 people
- Sponsor
- AbbVie